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Abstract: Abuse of designer drugs such as synthetic cathinones presents a challenge to both 
medical and forensic experts.  Detecting cathinone exposure in humans requires a sensitive, 
reliable method and treatment involves an understanding of the physiological response of 
the body to these novel compounds.  This study focused on developing a liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method for the detection and 
quantitation of sixteen popular synthetic cathinone analogues.  The method was found to 
be linear from a lower limit of 1ng/ml-10ng/ml, depending on the drug, to an upper limit 
of 25ng/ml for all tested drugs.  This LC-MS/MS method was then employed to study the 
interaction of specific bath salts, mephedrone (MEPH) and buphedrone (BUPH), with 
cytochrome p450 (CYP) enzyme systems.  The IC50s of MEPH and BUPH were 
determined to be 10.1 µM and 61.7 µM, respectively, using a fluorescence-based CYP2D6 
inhibitor screening kit, demonstrating an inhibiting interaction with CYP2D6.  A human 
liver microsomal preparation consisting of 20 Phase I metabolic enzymes was then tested 
with MEPH and BUPH, which demonstrated no significant change in parent compound 
concentration over the course of an hour.  These findings suggest that MEPH and BUPH 
act as a CYP2D6 inhibitors, but are not metabolized as a substrate by the enzymes in the 
test system.  
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CHAPTER I 
 
 
INTRODUCTION 
 
According to a 2011 survey performed by the Substance Abuse and Mental Health 
Service Administration, 22.5 million Americans self-reported as current illicit drug users.1  
Despite these reported illicit drug users, the Federal Bureau of Investigation’s Uniform 
Crime Reporting (UCR) Program found that only 1.5 million were arrested that year.2  
Additionally, 25% of the 5.1 million patients treated for drug-related injuries in 2011 were 
being treated for symptoms brought on by an recreational drug use.3  These data 
demonstrate that drug abuse presents a significant threat to both the health of individuals 
and to the public health.  The first step in treating or prosecuting illegal drug exposure is 
the detection of the consumed drug.  Synthetic cathinones, colloquially known as “bath 
salts” or “plant food”, 4 can pose a significant problem as many forensic and clinical 
toxicology laboratories do not have methods to detect this class of novel synthetic drugs.  
A hallmark of the synthetic drug market is its malleability; a manufacturer can alter 
a drug’s structure in an attempt to avoid detection and prosecution.  An analogue is a slight 
variation in the chemical structure of a drug (such as the transfer of a methyl group to a 
nearby carbon), while the resultant chemical remains in the same class of compounds.  As 
of 2011, 30 synthetic cathinones were documented;8 it is likely that there are more 
undocumented synthetic cathinone analogues which avoid detection.  Each analogue will 
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interact differently with a given method of detection; as new drugs are made, the method 
of detecting these drugs must be updated to include the most recent analogues.  In addition, 
cathinone analogues may interact with the body differently and have varying effects on 
enzymes, which may result in toxicity in situations that can cause life-threatening injury if 
their physiological effects are not anticipated, such as when a patient abuses cathinones 
when taking other, prescribed medications or is being treated for cathinone exposure. 
The ability to detect synthetic cathinones in exposed individuals is important for a 
number of reasons.  First, when prosecuting an individual for illicit drug consumption or 
manufacturing, the forensic investigator’s case is greatly strengthened if the investigators 
are able to determine the identity of the compound in question and whether or not the 
concentration in the body is capable of causing a physiological effect.  Second, effective 
medical treatment of illicit drug exposure often involves identifying the specific drug the 
individual has consumed because different drugs will bring about different physiological 
effects.  Treatment and addiction rehabilitation may vary from one drug to the next and a 
medical professional will be able to more effectively treat their patient with all of the 
necessary information, including an understanding of cathinone metabolism.  Third, 
cathinone use and abuse result in fatalities, and the detection of a broad array of these 
compounds will be of benefit to death investigators.  Finally, this study would also 
potentially improve cathinone detection in vivo as novel, long-lasting metabolic products 
are identified that might be the targets of new analytical method.
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Several studies in the literature identify methods for determining the concentration 
of synthetic cathinones in various biological specimens.  This endeavor often employs 
analytical instrumentation that consists of a chromatographic separation followed by 
analysis of the drug via mass spectrometry.  Of the methods available, liquid 
chromatography has experienced the greatest success and is the most common method 
employed for synthetic cathinone detection by researchers and forensic experts.5-7  While 
methods for the detection and quantitation of synthetic cathinones exist, the rapidly 
changing designer drug landscape requires researchers to constantly develop new methods. 
One of the challenges involved in synthetic cathinone detection is the ability to 
acquire calibrated drug standards.  Synthetic cathinones are Schedule I drugs, and only 
licensed institutions are permitted to acquire drug standards for the study of these 
compounds.  The Oklahoma State University Forensic Toxicology and Trace Laboratory 
(FTTL) is an institution permitted to study synthetic cathinones, thus offering an 
exceptional opportunity to add to the literature on synthetic cathinone detection and address 
the largely unexplored area of cathinone metabolism. 
 The purpose of this research is to develop a method for the detection and 
quantitation of synthetic cathinones and a subsequent investigation of the metabolism of 
synthetic cathinones using commercially available, human-derived hepatic enzymes. The 
cathinone analogues in this study were chosen based on high popularity and structural 
diversity, and the results of this study were then statistically evaluated for significance.  
The resulting LC-MS/MS detection method could be employed by law enforcement 
agencies to quantify these compounds in biological samples, allowing these agencies to 
prosecute synthetic cathinone drug users and dealers.  The metabolism investigation can 
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help physicians make more informed treatment decisions, provide information to the death 
investigation process, and lead to better detection as metabolites are identified as analytical 
targets.
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
2.1. Introduction 
Illegal drug use is a growing problem worldwide.  According to the Federal Bureau 
of Investigation’s Uniform Crime Reporting (UCR) Program, the highest number of arrests 
in the year 2011 was for drug abuse violations with over 1.5 million of the 12.4 million 
arrests made that year.2  In the same year, an estimated 22.5 million Americans 12 years of 
age or older self-reported as current illicit drug users (defined by the study as having used 
illicit drugs within a month prior to being interviewed).1  The nature of a self-reported 
survey tends to lean toward an underestimation of the true number, in reality the number 
of drug abusers in the United States is likely much higher.  While the number of arrests for 
drug abuse violations is incredibly high, the number of unconvicted illicit drug users is 
substantially higher.  The sheer volume of arrests for drug abuse violations and the number 
of drug abusers present a substantial need for a method that allows for the accurate 
detection and quantitation of the drugs an individual may be taking.  Detection and 
quantitation is the first step in combatting the illicit drug epidemic.   
In addition to the legal ramifications, illicit drug exposure is a danger to the health 
of those exposed.  Drug-related injuries are becoming more commonplace and present a 
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significant risk to the health of citizens both in the United States and abroad.  In the United 
States, 5.1 million patients visited emergency departments for drug-related injuries in 2011, 
and 25% of those patient visits were attributed to illicit drugs.3  Emergency department 
visits increased by nearly three hundred thousand visits per year between 2009 and 2011 
for patients being treated for symptoms brought on by recreational drug use.3  More 
emergency department visits can be attributed to drug abuse injuries than ever before.  As 
such, the need for a method of detecting the specific drugs affecting a patient and an 
understanding of the drug’s metabolic effects is necessary for the appropriate treatment of 
patient exposure. 
The Controlled Substances Act of 1970 laid much of the groundwork for the 
regulation of illicit drugs.  This act established guidelines for the scheduling of various 
drugs based on the drug’s FDA-approved medical uses, potential for abuse, and potential 
for physical and/or psychological dependence.9  Drugs that presented a significant threat 
to an individual’s health without offering an appropriate therapeutic benefit—
methamphetamine, cocaine, and heroine, for example—were quickly scheduled and then 
highly regulated by government officials.   To circumvent legislation, drug manufacturers 
began seeking out alternative drugs that would have similar physiological effects as their 
scheduled counterparts, but would not be burdened by the scrutiny of government officials.  
These novel drugs that could avoid legislative repercussion were termed “designer drugs” 
and are challenging to regulate. 
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2.2 Designer Drugs 
Many designer drugs were originally synthesized for research or medical purposes 
by scientists in academia or in the pharmaceutical industry.  Initially these classes of drugs 
were unregulated and available to the public, until they were repurposed for recreational 
use and became drugs of abuse.  A notorious example is 3,4-methylenedioxy-
methamphetamine (MDMA, also known as ecstasy), a compound first synthesized in 1912 
by Merck Pharmaceuticals as a parent compound to synthesize other pharmaceuticals.  
MDMA reappeared in the streets in the 1970s shortly after psychiatrists had begun utilizing 
it as a psychotherapeutic tool.  Even then it was not extensively abused until the 1980s as 
a popular “party drug” and was federally scheduled in 1985.10 
Designer drugs have functional similarities to other drugs of abuse but not are not 
structurally identical, allowing them to elude government regulation under the Controlled 
Substances Act.  The designer drug phenomenon prompted the Controlled Substance 
Analogue Enforcement Act of 1986, which widened the scope of the 1970 law.  The new 
act prohibited substances intended for human consumption that shared similar structures 
and physiological effects with other drugs of abuse.11  An unfortunate side effect of the 
Controlled Substance Analogue Enforcement Act is that it makes many of the analogues 
Schedule I, which slows research on illicit drug analogues as fewer laboratories have 
licensing to access Schedule I drugs.  This can be severely detrimental in responding to the 
fast-moving designer drug industry.  The Oklahoma State University Forensic Toxicology 
and Trace Laboratory (FTTL), where this research was performed, has the necessary 
licensing to carry out research with Schedule I compounds and help address this current 
public health problem. 
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Even with the wider scope of the Controlled Substance Analogue Enforcement Act, 
two potential pathways exist for illicit drug manufacturers to circumvent the latest 
legislation.  A manufacturer can synthesize a new compound that achieves similar 
stimulant, depressant, or hallucinogenic effects of its scheduled counterpart with a 
significantly different structure.12  Alternatively, a manufacturer can label a drug as “not 
for human consumption.”  The latter pathway is particularly common amongst synthetic 
cathinones and synthetic cannabinoids, which are often labelled as “bath salts” and “spice,” 
respectively.4,13  
 
2.3. Synthetic Cathinones 
Following the trend of many other designer drugs before them, synthetic cathinones 
are a class of psychoactive compounds derived from cathinone, a naturally occurring 
stimulant.  Cathinone is found in the leaves of khat, which is native to parts of Africa and 
the Arabian Peninsula and is often chewed to achieve the desired stimulation.14  
Methcathinone, a methylated analogue of cathinone, was first synthesized in 192815 and 
represents the first of many synthetic cathinones that would later serve as “legal 
alternatives” to MDMA and other, previously scheduled, drugs of abuse.  Synthetic 
cathinones are a class of compounds capable of a wide-range structural modification; the 
variety of structural analogues make them difficult to detect and regulate and their 
biological consequences even more difficult to predict. 
9 
 
Structurally, synthetic cathinones share a common backbone of a phenethylamine 
with a ketone group at the β carbon (See Figure 1).  From this common backbone, the 
functional groups are extremely diverse, thereby giving cathinones potential for varying 
chemical structure and physiological effects.  The trademark characteristic of synthetic 
cathinones is their malleable composition; as 
soon as a given analogue is scheduled, another 
is synthesized to meet consumer needs and to 
circumvent federal legislation.  For example, 
methylenedioxypyrovalerone (MDPV) is 
capable of acting as a dopamine uptake 
inhibitor and was designed to be more potent 
than cocaine, producing intense stimulation and euphoria.16  MDPV epitomizes the illicit 
drug manufacturer strategy of utilizing an existing compound that can emulate previously 
scheduled drugs, and repurposing it for recreational use.  A different combination of 
functional groups could lead to a different a physiological effect and a different response 
to a method of detection.  Synthetic cathinones’ broad range of possible analogues make 
them ideal candidates for designer drug producers and has led to a spike in cathinone 
popularity in recent years. 
 Bath salts have begun replacing MDMA as the party drug of choice in many 
European countries.  Mephedrone (MEPH), a synthetic cathinone analogue, is gaining 
popularity because of the decreasing purity of both cocaine and MDMA.17  Consumers are 
able to purchase MEPH at a lower price than either MDMA or cocaine and achieve greater 
stimulation.  Cathinones are viewed as a more reliable and safer replacement to MDMA 
Figure 1.  Structure of synthetic cathinone, 
MDPV. 
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and cocaine, which may add to their recent popularity both in Europe and in the United 
States.  Based on recent surveys, the main settings of use include nightclubs and parties 
and the Internet is the most common avenue utilized by designer drug dealers to market 
their product.18 
 Synthetic cathinones’ popularity rise in recent years can also be attributed to 
information sharing, advertising, and marketing through the Internet.  Online shops have 
increased the marketability of designer drugs because online shops are known for their 
adaptability to changing legislation and customer needs.19  An online shop’s flexibility, in 
addition to its ability to serve a wide customer base, allows illicit drug marketers to sell the 
most recent designer drugs to a large number of drug abusers.  Another challenge presented 
by designer drugs is the fact that the exposure population is drastically increased when 
unscheduled drugs can be purchased legally in gas stations, convenience stores, tobacco 
shops, and head shops before legislation is able to effectively ban these structurally fluid 
compounds. 
 
2.4. Synthetic Cathinone Detection 
 The scientific community has recognized the need to study synthetic cathinones 
and has developed several methods for their detection.  Analytical methods have been used 
by various studies to detect and quantify synthetic cathinone concentrations in a variety of 
biological sources.  Chromatographic separation, a standard technique in many analytical 
laboratories, consists of passing analytes of interest through a column, separating the 
analytes based on their affinity to the column.  Due to its convenience, liquid 
chromatography (LC) is the most common method for separation of the various synthetic 
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cathinone analogues.  Another chromatography method, gas chromatography (GC), is 
limited by the additional analytical steps required to reach the desired product compared to 
LC.20  GC requires the analytes in the gas phase while LC requires that the analytes are in 
the aqueous phase; thus GC is only applicable if the compound is adequately volatile.  Mass 
spectrometry (MS) is a common method for analyte quantitation and is, overwhelmingly, 
the most widely used method for quantifying synthetic cathinone concentrations. 
Scientists have been shown that synthetic cathinones and their metabolites are 
deposited throughout the body after consumption.  As such, a variety of biological 
specimens can be used in the detection of synthetic cathinones.  Marinetti and Antonides 
were able to demonstrate that synthetic cathinones were retained in many biological 
samples including whole blood, plasma, urine, vitreous humor fluid, cerebrospinal fluid, 
bile, and tissue homogenates.21  Each of these biological sources can be utilized in the 
detection of synthetic cathinones in both postmortem and human performance 
toxicological analyses.  In addition to the above biological sources, Shah et al were able to 
utilize hair as a biological source for synthetic cathinone testing.7  Hair is capable of 
providing long term information about the history of drug exposure, making it a potentially 
valuable source for forensic testing.  A wide variety of samples are useful in situations 
where a certain sample type may become contaminated or is unavailable.   
Both liquid and gas chromatography separation techniques have proven of 
detecting and quantifying synthetic cathinone concentrations.  LC-MS/MS (liquid 
chromatography coupled tandem mass spectrometry) screening appears to be the most 
widely used method of synthetic cathinone detection.5,6,22 Scientists have also found 
limited success using GC-MS (gas chromatography coupled mass spectrometry) to 
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dissociate various synthetic cathinone analogues.21  Additionally, Meyer et al. found that 
to reliably detect some synthetic cathinones using GC-MS, enzyme digestion and 
derivatization were necessary.20  The added digestion and derivatization increase both the 
cost and the time required to achieve successful quantitation of the synthetic cathinones.  
Due to its direct detection (without added derivatization), LC-MS/MS appears to be the 
more effective method for synthetic cathinone detection based on previous studies. 
 
2.5. Synthetic Cathinone Physiological Effects 
Permission must be granted by the Drug Enforcement Administration before 
researchers can acquire Schedule I drugs, contributing to the fact that few case studies have 
formally examined the physiological effects of these drugs.  A small number of published 
case studies provide some insight into the symptoms that can be expected with synthetic 
cathinone exposure.  In general, the effects of cathinone exposure are cardiovascular and 
neurological in nature and can include combative behavior, excited delirium, 
hallucinations, and abnormal rapid heart rate.23  Prolonged symptoms can lead to 
permanent nervous or cardiovascular damage and eventually death.  
Excited delirium is a side effect of synthetic cathinone exposure that presents a 
significant challenge to healthcare professionals.  Drug side effects are typically only 
harmful to the individuals exposed to the drug, however, excited delirium makes the 
exposed individual a danger to themselves and others around them.  Law enforcement 
officials and emergency health professionals are particularly vulnerable to individuals 
afflicted by an excited delirium as they attempt to apprehend and subsequently medically 
treat the affected person.  This agitated state is typically characterized by hallucinations, 
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paranoid delusions, violent behavior, destruction of skeletal muscle, and eventually kidney 
failure.24,25  The effects of these synthetic compounds have been observed from the surface, 
but there is little information regarding their effects within the body which would provide 
information about the mechanism that is bringing on the adverse drug reactions and how 
to safely handle these intoxicated individuals. 
Many of the methods commonly used to control violent behavior, such as physical 
restraints, electronic control devices (TASER), and antipsychotic drugs, have the potential 
to lead to severe medical complications due to the exacerbation of preexisting 
physiological symptoms.26  Excited delirium also makes the patients resistant to sedatives, 
further complicating treatment.  In one case report, emergency medical professionals noted 
that a 30-year-old male with no prior mental disorder exhibited a “very high tolerance to 
sedatives and analgesics” when the patient was admitted to the emergency department 
exhibiting symptoms of agitation, violent behavior, and abrupt change in mental status.27  
The mechanism of this phenomenon is currently unexplained.  Insight into the metabolism 
of synthetic cathinones may lead to a more effective way to sedate exposed individuals and 
safely treat them. 
While the variety of biological sources available for testing demonstrates that 
synthetic cathinones are widely distributed throughout the body, the metabolism and 
elimination of the drug are not well understood.  A better understanding of synthetic 
cathinone’s mechanism of action is necessary to provide healthcare workers with the 
necessary information to optimize patient treatment and ensure the safety of the patient and 
those around them.  By studying this class of drug’s interaction with metabolic enzymes, a 
cause can be linked to the observed physiological outcome.  A systematic investigation of 
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both the detection and metabolism of synthetic cathinones will arm healthcare providers 
and forensic investigators with the necessary information to counteract this dangerous 
designer drug. 
 
2.6. Synthetic Cathinone Metabolism 
 Synthetic cathinones are relatively novel compounds, so the metabolism of many 
analogues is currently not well understood.  Due to its popularity, MEPH has faced a more 
rigorous scrutiny compared to other synthetic cathinone analogues.  MEPH metabolism 
has been hypothesized to 
involve an N-demethylation to 
the primary amine, reduction of 
the ketone to an alcohol, and 
oxidation of the tolyl to the 
corresponding alcohol and 
carboxylic acid (see Figure 2).28  
Pedersen et al. used cDNA-
expressed CYP enzymes and 
human liver microsomal 
preparations to study MEPH 
metabolism and attributed its 
Phase I metabolism to 
cytochrome P450 2D6 (CYP2D6) with minor contributions from other NAPDH-dependent 
enzymes.29  Currently, the metabolism of BUPH has only been indirectly observed by 
Figure 2.  Proposed scheme for the Phase 1 
metabolism of mephedrone in rats and humans.  
Metabolite 5 should only be found in human urine 
samples. 
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comparing the excreted products to the ingested parent drug.  BUPH is thought to go 
through a reduction of the beta-keto group and an N-dealkylation, based on metabolites 
found in patient urine who had been exposed to BUPH.30  MEPH and BUPH were the 
selected cathinones investigated in this study. 
Drug-drug interactions are a constant concern in hospital settings.  Drugs that 
attempt to utilize the same enzyme during metabolism are going to interact based their 
specific active sites on the enzyme and their relative affinities for the enzyme.  Cathinone 
ingestion commonly occurs alongside other drugs or alcohol31,32 leaving these individuals 
at a heightened risk for drug-drug interactions even before physicians attempt to begin 
treatment of exposure.  Administering drugs during treatment may worsen the symptoms 
associated with poly-drug toxicity.  By characterizing synthetic cathinone metabolism, 
physicians will be able to make informed decisions and avoid harmful drug-drug 
interactions and adverse drug reactions which may endanger the patient.  Though a public 
menace, synthetic cathinones are still widely understudied and further investigation of their 
metabolism could aid in the efforts of both detection and treatment. 
 
2.7. Conclusion 
The literature demonstrates that illicit drug exposure is a significant problem for 
both law enforcement officials and healthcare providers.   The purpose of this research is 
to meet the need of forensic and clinical laboratories by developing a method for the 
detection and quantitation of synthetic cathinones.  This detection method will then be used 
in a subsequent investigation of the metabolism of synthetic cathinones using human liver 
microsomes to address the deficit within the literature regarding the metabolic pathway of 
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synthetic cathinones.  A greater understanding of synthetic cathinone metabolism can be 
used to better provide treatment to exposed individuals in both emergency and 
rehabilitative areas of medicine.  The resulting method and metabolic investigation can be 
employed by law enforcement agencies and emergency medical professionals to more 
effectively handle individuals exposed to these dangerous compounds.
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CHAPTER III 
 
 
METHODOLOGY 
 
3.1 Introduction 
This method development and metabolism study was performed at the Oklahoma 
State University Center for Health Sciences Forensic Toxicology and Trace Laboratory, 
which is licensed to handle Schedule I drugs such as synthetic cathinones.  Method 
development and metabolic inquiry was approved by the Oklahoma State University 
Institutional Review Board.  Instrument parameters were established on a liquid 
chromatograph coupled mass spectrometer (LC-MS/MS) using calibrated reference 
standards.  Metabolism studies were performed using enzyme inhibitor screening kits and 
human liver microsomal fractions.  Following the incubation of cathinones with enzyme, 
the enzymatic action was observed using both fluorescence spectroscopy and mass 
spectrometry. 
 
3.2 LC-MS/MS Method Development 
Instrumentation utilized by this method is common in many toxicology laboratories 
allowing laboratories to adopt the detection method without acquiring expensive auxiliary 
instrumentation.  The prepared calibrator samples and the microsomal fractions were 
analyzed with a Shimadzu (Kyoto, Japan) liquid chromatograph coupled to an AB Sciex 
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(Framingham, MA) triple quadrupole tandem mass spectrometer with electron spray 
ionization (Figure 3).  Analytes were separated using a Chromegabond Wide Range C18 
LC column (particle size: 5µ, pore size: 120Å, dimensions: 15cm x 2.1mm) manufactured 
by ES Industries (West Berlin, NJ).  The separated analytes then travelled to the MS/MS 
where they were ionized and quantified in multiple reaction monitoring (MRM) mode with 
positive electron spray ionization using at least two MRM transitions for qualification.   
 
HPLC grade acetonitrile, methanol, ammonium formate, and formic acid were 
purchased from VWR International (Radnor, PA).  To prepare samples for injection, 20uL 
of a 625 ng/mL internal standard solution (except for MEPH (metabolite)-D3 which was 
prepared at twice the concentration of the others) and 30uL of phosphate buffer (pH 4.5) 
was added to 50 µL of sample.  150 µL of sample diluent made of a ratio of 95% the 
aqueous mobile phase (mobile phase A) and 5% of the organic mobile phase (mobile phase 
B) and was added to the previous 100uL for a total 250uL total prepared sample.  Mobile 
Figure 3.  Photograph of LC-MS/MS used in method development. 
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phase A consisted of a 2mM ammonium formate solution in water with .1% formic acid 
and mobile phase B consisted of a 9:1 acetonitrile:water solution with .1% formic acid. 
This sample preparation was purposefully designed to mimic the conditions of the 
solution flowing through the instrument so that their chromatography was more consistent.  
Phosphate buffer was used to neutralize fluctuations in pH, which can also cause variations 
in chromatography.  Internal standards were run in solution with samples to provide a 
baseline point of comparison of known concentration and allowed for the quantitation of 
unknown sample concentrations.  This was done by comparing the instrument response (in 
the form of peak area ratio) of calibrators with known standard concentration to the 
instrument response of unknown samples.  After the samples were appropriately diluted 
they were ready for injection onto the instrument. 
 
3.2.1 Liquid Chromatograph Conditions 
Liquid chromatography is used to separate drugs within a sample from each other 
by their various affinities as they travel through a functionalized column.  Compounds with 
a high affinity for the column will “cling” to the column and move more slowly than those 
with a lower affinity.  This process is especially important for synthetic cathinones, which 
can have similar fragmentation patterns in the mass spectrometer, making them impossible 
to dissociate from one another using a mass spectrometer alone.  Chromatography was 
optimized using a drug standard mix and an internal standard mix.  Internal standards 
interact similarly to separation methods as their non-deuterated counterparts and allow the 
instrumentation to quantify the concentration of the drug being analyzed by providing a 
compound for comparison that differs only in mass, not in functionality. 
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All drug standards and deuterated internal standards were acquired from Cerilliant 
(Round Rock, TX) as calibrated reference standards in methanol at 1 mg/ml and 100 µg/ml 
respectively (See Table 1 for complete list).   
Table 1. Drug standards and internal standards and their corresponding concentrations. 
Drug Standards Concentration Internal Standards Concentration 
3-Fluoromethcathinone 1 mg/ml 
(±)-4-Methylephedrine  
(Mephedrone 
Metabolite)-D3 100 µg/ml 
(±)-3-
Fluoromethcathinone 
Ephedrine Metabolite  1 mg/ml Alpha-PVP-D8 100 µg/ml 
(±)-4-Methylephedrine  
(Mephedrone Metabolite) 1 mg/ml 
Buphedrone Ephedrine 
Metabolite-D3 100 µg/ml 
Alpha-PVP  1 mg/ml Butylone-D3  100 µg/ml 
Buphedrone  1 mg/ml Ethylone-D5  100 µg/ml 
Buphedrone Ephedrine 
Metabolite  1 mg/ml 
3,4-Methylenedioxy 
Pyrovalerone-D8 100 µg/ml 
Butylone  1 mg/ml Mephedrone-D3  100 µg/ml 
Ethylone  1 mg/ml Methylone-D3  100 µg/ml 
Mephedrone  1 mg/ml Naphyrone-D5  100 µg/ml 
Methedrone  1 mg/ml 
(±)-N-Ethylcathinone 
Ephedrine Metabolite-
D5 100 µg/ml 
Methylone  1 mg/ml Pentylone-D3  100 µg/ml 
Naphyrone  1 mg/ml     
N-Ethylcathinone  1 mg/ml     
(±)-N-Ethylcathinone 
Ephedrine Metabolite ,   1 mg/ml     
Pentylone  1 mg/ml     
Pyrovalerone  1 mg/ml     
 
Drug standards and internal standards were diluted to 100 ng/ml in methanol for 
examination by LC-MS/MS.  Chromatographic separation was a modified version of that 
performed by Swortwood and Boland5 and consisted of using varying ratios of mobile 
phase A (consisting of a 2mM ammonium formate/.1% formic acid solution in water) and 
mobile phase B (consisting of a 90% acetonitrile and 10% water solution by volume with 
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.1% formic acid).  The gradient of mobile phase A to mobile phase B proceeded as follows: 
5% B up to 15% B in seven minutes, next a one minute ramp to 35% B, then an increase 
to 95% B over one minute where the ratio is held constant for one minute, and lastly a three 
minute re-equilibration at 5% B to prepare the LC for the next sample (Figure 4).   
 
 
The gradient was performed with a flow rate of .5 mL/min throughout.  The column was 
kept at 40oC in a column oven.  From the LC, the compounds flow directly into the tandem 
mass spectrometer so that the separated compounds can be quantified. 
 
Figure 4.  Diagram of the LC time program, which shows the change of mobile phase 
ratio as the LC separates the compounds according to their affinities to the stationary 
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3.2.2 Mass Spectrometer 
A mass spectrometer uses high temperatures and voltages to fragment a compound 
into smaller constituent components.  The MS detector was optimized to detect specific 
fragments of each ionized compound using Lab Solutions Software which was then used 
to quantify the cathinones.  The optimization process involves fragmenting the analytes at 
varying energies and recording the instrument response at each energy in terms of peak 
intensity.  The energies and ion fragments that corresponded to the highest instrument 
response were included in the method. A combination of a precursor and product ion is 
called an MRM (multiple reaction monitoring), and at least two MRM transitions were 
used for each compound (See Table 2).  The entrance potential for each analyte was 10V. 
 
Table 2. Each cathinone included in the LC-MS/MS method with their corresponding 
optimized ion fragments and MS fragmentation energies. 
Compound Name 
Precursor 
Ion 
Product 
Ion 
Collision 
Energy 
Collision 
Exit 
Potential 
Dependent 
Parameters 
3-FMC 182.013 163.939 19 8 56 
    149.118 29 24 56 
    148.405 41 24 56 
3-FMC (metabolite) 184.008 151.2 31 6 51 
    150.665 31 24 51 
    114.8 37 18 51 
Mephedrone 
(metabolite) 
179.916 91.081 59 28 21 
    116.258 39 52 21 
    115.068 65 54 21 
    104.962 31 6 21 
    77.018 87 2 21 
Alpha-PVP 233.267 91.316 33 4 61 
    92 33 14 61 
  
 
 
 
  77.182 69 10 61 
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Buphedrone 177.930 159.934 19 22 31 
    130.804 33 10 31 
    129.673 45 20 31 
Buphedrone Ephedrine 181.091 163.039 19 10 41 
    91.6 39 14 41 
    92.167 39 4 41 
Butylone 223.121 175.011 25 14 46 
    204.989 21 10 46 
    147.098 37 24 46 
Ethylone 223.435 91.556 43 18 61 
    118.537 43 22 61 
    119.179 43 8 61 
Mephedrone 178.043 144.87 29 12 51 
    143.81 41 24 51 
    91.092 47 12 51 
    77.25 71 0 51 
    119.233 31 18 51 
Methedrone 194.990 162.054 29 6 51 
    147.141 39 24 51 
    146.8 39 6 51 
Methylone 207.990 160.165 27 24 36 
    159.673 27 6 36 
    132.014 39 22 36 
Naphyrone 282.044 141.082 35 6 81 
    126.836 77 18 81 
    125.872 41 4 81 
N-ethylcathinone 179.090 132.77 27 6 51 
    131.57 29 20 51 
    130.859 37 6 51 
    118.344 29 18 51 
    106.037 33 16 51 
N-ethylcathinone 
(metabolite) 
180.995 139.79 11 22 51 
    117.834 31 18 51 
    115.839 39 18 51 
Pentylone 235.975 187.887 25 8 31 
    174.918 31 14 31 
    131.061 51 10 31 
Pyrovalerone 247.099 105.23 37 6 61 
    106.247 37 16 61 
    90.987 63 14 61 
24 
 
Mephedrone 
(metabolite)-D3 
184.676 91 41 14 51 
    98 21 14 51 
    131.1 27 6 51 
Alpha-PVP-D8 240.110 91.099 37 14 71 
    77.387 71 0 71 
    134.206 43 10 71 
Buphedrone 
(metabolite)-D3 
183.028 136.1 31 6 46 
    91 37 14 46 
    98 23 14 46 
Butylone-D3 226.498 178.247 25 6 51 
    207.859 17 12 51 
    135.078 47 10 51 
Ethylone-D5 227.001 179.021 27 8 51 
    151.216 29 8 51 
    119.139 45 18 51 
MDPV-D8 284.032 134.594 41 6 71 
    204.95 27 10 71 
    174.9 33 8 71 
Mephedrone-D3 181.023 148.208 31 10 56 
    147.586 33 26 56 
    144.969 27 6 56 
Methylone-D3 211.003 163.029 25 24 41 
    135.041 39 10 41 
    91.233 55 4 41 
Naphyrone-D5 287.112 216.091 27 10 81 
    141.171 39 6 81 
    142.16 37 10 81 
 
 
N-ethylcathinone 
(metabolite)-D5 
 
 
186.005 
 
 
108.989 
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41 
    117.955 31 18 41 
    115.908 41 8 41 
Pentylone-D3 239.052 191.204 27 10 61 
    134.404 51 20 61 
    204.914 19 20 61 
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3.4 Enzyme Inhibitor Screening 
Enzyme screening kit and human liver microsomal fractions were purchased from 
Corning Inc. (Corning, NY).  The CYP2D6/AMMC High Throughput kit was used to 
evaluate inhibition of CYP2D6 activity by quinidine, cimetidine, MEPH, and BUPH.  The 
control drugs, quinidine and cimetidine, were chosen based on the fact that they are 
documented CYP2D6 inhibitors.33  MEPH and BUPH were chosen as the cathinones to be 
studied because a drug standard of a metabolite was commercially available.  This would 
allow for the observation of changes in parent concentration and any subsequent changes 
in metabolite concentration.  The enzyme inhibition was monitored using a fluorescence 
plate reader manufactured by BioTek (Winooski, VT). 
The enzyme screening kit utilizes the fluorescent property of 3-[2-(N,N-diethyl-N-
methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC) metabolism to investigate 
cathinone analogue inhibition of CYP2D6 activity.  The compound of interest inhibits 
CYP2D6 and the AMMC is not converted to its fluorescent metabolite 3-[2-(N,N-diethyl-
N-methylammonium)ethyl]-7-hydroxy-4-methylcoumarin (AMHC) producing a lower 
intensity of fluorescence which can be observed with the fluorescence plate reader.  The 
assay protocol was essentially as described by the manufacturer.    The analyte of interest, 
at concentrations varying from 1µM to .003µM, was combined with a cofactor mix in a 
96-well plate and incubated for ten minutes to prepare the solution for the enzyme.  The 
enzyme was added and the plate was covered and incubated for thirty minutes in an oven 
at 37oC and then the reaction was stopped with a Tris Base stop solution.  Each plate also 
contained the appropriate enzyme and assay controls (See Figure 5).  The plate was then 
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analyzed by a plate reader (390nm excitation and 460nm emission) to determine 
fluorescence intensity of each well. 
 
 
3.5 Microsomal Preparation 
A Corning Mammalian Liver Cytosol Assay was used to investigate synthetic 
cathinone metabolism in the presence of twenty metabolic enzymes (Table 3) over the 
course of an hour.  The microsomal preparation was altered from manufacturer 
specifications to provide a higher instrument response when the samples were analyzed 
and for a greater enzyme action.  8.4uL of MEPH or BUPH drug stock (1 mg/ml) was 
diluted with HPLC water to a final concentration of 2.8µg/ml.  Both cathinones were 
Figure 5.  Diagram of CYP2D6 inhibitor screening kit plate layout.   
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diluted to a final concentration of 2µg/ml after the addition of all of the solutions which 
included: 500mM potassium phosphate buffer, acetyl-CoA, and PAPS then incubated at 
37oC for ten minutes to prepare the solution for the addition of the enzyme mixture.  After 
incubation, the enzyme mixture was added to each well except the zero time point.  The 
wells were incubated for an hour and specific wells were stopped with 100 µL of 
acetonitrile at 20, 40, and 60 minute time points to observe the drug-enzyme action over 
time (Figure 6).  The wells were diluted according to the LC-MS/MS sample preparation 
(as discussed previously), and analyzed to determine the concentration of synthetic 
cathinone after incubation. 
 
 
Table 3.  List of enzymes present in the microsomal preparation. 
Microsomal Preparation Enzymes 
OR CYP2C19 UGT1A4 
Cytochrome b5 CYP2D6 UGT1A6 
CYP1A2 CYP2E1 UGT1A9 
CYP2A6 CYP3A4 UGT2B7 
CYP2B6 CYP4A11 CYP3A4 
CYP2C8 FMO CYP3A5 
CYP2C9 UGT1A1   
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3.6 Data Analysis 
The LC-MS/MS quantitation method efficiency was evaluated based on the 
accuracy and the upper and lower limits of detection.  Limits of detection include the upper 
limit where the detector of the MS becomes saturated and is no longer able to accurately 
determine the concentration of analyte.  The lower limit of detection is the smallest 
concentration of drug able to be accurately quantified.  Accuracy refers to the method’s 
ability measure a cathinone concentration close to that of the true value through the use of 
spiked samples of known concentration.  A calibration curve was prepared at seven 
different concentrations ranging from 25ng/mL to 1ng/mL and quality control solutions 
were prepared separately at 15, 7.5, and 2 ng/mL to evaluate the accuracy of the 
concentrations being calculated.  Calibrators were considered accurate if they were 
Figure 6.  Diagram of microsomal preparation plate layout.   
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calculated to be within 15% of their prepared concentration while quality controls were 
considered accurate if they were within 20% of their prepared concentration.  Only after 
the LC-MS/MS was demonstrated to be accurate was it used in the microsomal preparation 
study. 
The change in fluorescent intensity was used to determine the concentration of the 
inhibitor that inhibited 50% of the AMMC conversion to its fluorescent product, AMHC 
(IC50).  The IC50s of each analyte (quinidine, cimetidine, MEPH, and BUPH) were 
compared statistically using nonlinear curve fitting for using GraphPad Prism Software 
(v6.03, San Diego, CA).  The assumption of normal distribution was not made, and 
analyses were performed using Kruskal-Wallis analysis of variance.  Potential outliers 
within the data were examined with the Grubb’s test (α=0.05) prior to Kruskal-Wallis 
analysis.  In the microsomal assays, one-way analysis of variance (1-way ANOVA) was 
performed to determine if the concentrations of the parent drug changed over time (simple 
time-effect).   
 
3.7 Methods Summary  
This method was systematically developed using known cathinone calibrators 
available commercially.  Equipment, materials, and instrumentation are common and 
obtainable by a variety of clinical and forensic laboratories, allowing them to apply any 
derived methodology.  Cathinones were diluted using a specific sample preparation to 
provide optimal peak shape and protect the instrumentation and then injected onto an LC-
MS/MS for quantitation.  After chromatography parameters had been established and 
cathinones had been successfully detected, the method was used to study solutions after 
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microsomal preparation to determine which enzymes are acting on MEPH and BUPH in 
the body.  
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CHAPTER IV 
 
 
RESULTS 
 
4.1 METHOD ACCURACY AND LINEARITY 
 Cathinone analogues are structurally similar (though not identical) from one 
compound to the next, making chromatographic separation of differing analogues a 
challenge.  Chromatographic separation was the first problem to be addressed, using drug 
standards in methanol.  Adequate chromatographic separation was demonstrated when 
baseline separation was achieved for each analyte peak.  Afterward, prepared calibrator 
and quality control samples were analyzed to determine the limits of quantitation of the 
sample preparation being used.  All prepared calibrators were diluted according to the 
protocol outlined in the methods section in order to simulate the conditions of unknown 
sample solutions.  Table 3 lists the limit of quantitation of the sixteen cathinones included 
in the LC-MS/MS method.  Limits were decided based on accuracy, precision, peak shape, 
and peak quality.  After calibrators and quality controls were within the desired accuracy 
ranges, the LC-MS/MS method was deemed ready for application to the study of synthetic 
cathinone metabolism. 
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4.2 CYP2D6 INHIBITOR SCREENING RESULTS 
 The investigation of MEPH and BUPH metabolism started with an investigation 
into their activity on the liver enzyme typically associated with the metabolism and 
elimination of many xenobiotics, CYP2D6.  Quinidine, cimetidine, MEPH, and BUPH 
inhibition of CYP2D6 was investigated using a Corning CYP2D6 inhibitor screening kit 
with the intent of determining their respective affinities to CYP2D6.  The activity of 
quinidine on CYP2D6 activity was investigated since it is reportedly one of the most potent 
of CYP2D6 inhibitors.  Cimetidine was included as a classic over-the-counter drug that has 
been shown to interfere with both CYP3A4 and CYP2D6 activity as an inhibitor.  The 
representative graph below shows quinidine’s inhibition curve replicates (Figure 7) as 
quinidine competes with AMMC for enzyme active sites.  The other inhibitors examined 
Table 4.  Each synthetic cathinone included in the LC-MS/MS method and 
the corresponding lower limit of quantitation for each analyte. 
Compound Name 
Lower Limit of 
Quantitation 
3-Fluoromethcathinone 1 ng/ml 
(±)-3-Fluoromethcathinone Ephedrine Metabolite  1 ng/ml 
(±)-4-Methylephedrine  (Mephedrone Metabolite) 1 ng/ml 
Alpha-PVP  2.5 ng/ml 
Buphedrone  1 ng/ml 
Buphedrone Ephedrine Metabolite  5 ng/ml 
Butylone  1 ng/ml 
Ethylone  10 ng/ml 
Mephedrone  1 ng/ml 
Methedrone  1 ng/ml 
Methylone  1 ng/ml 
Naphyrone  1 ng/ml 
N-Ethylcathinone  1.5 ng/ml 
(±)-N-Ethylcathinone Ephedrine Metabolite 1.5 ng/ml 
Pentylone  1 ng/ml 
Pyrovalerone  1.5 ng/ml 
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(cimetidine, MEPH, and BUPH) also have inhibition curves graphed in a similar manner.  
Predictably, the lowest concentration of test compound yields the highest fluorescence, as 
AMMC will occupy more CYP2D6 active sites and is converted to fluorescent AHMC. 
   
 
Collectively, analysis for each drug can then be plotted for graphical representation 
of CYP2D6 inhbition.  Quinidine (N=4), cimetidine (N=4), MEPH (N=5), and BUPH 
(N=5) were all analyzed in duplicate (Figure 8).   
Figure 7.  Nonlinear curve fitting for 4 independent assays using quinidine.  Data were 
fit by GraphPad Prism using nonlinear regression analysis and from these plots, 
individual IC50 values can be determined.  Each data point is the average of duplicate 
wells.     
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Percent inhibition was calculated by subtracting the fluorescence of the blank sample 
(baseline fluorescence) from the fluorescence intensity at a given point (inhibited 
fluorescence).  Dividing the resulting value by the quantity of the fluorescence achieved in 
the sample without inhibitor (control CYP2D6 activity) minus baseline fluorescence (see 
equation below). 
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Figure 8.  Composite graph of the log [analyte concentration] versus the percentage of 
total fluorescence observed. 
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Figure 9 shows a comparison of the maximum inhibition of CYP2D6 (which would 
occur at the highest concentrations of inhibitor and exhibits the lowest fluorescence 
intensity.  Maximum inhibition is a measure of drug’s efficacy towards an enzyme active 
site. 
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The graph shows the cimetidine is significantly different from the other three inhibitors 
(p<.05).  Meaning that high concentrations of cimetidine will not as readily inhibit 
CYP2D6 and lead to the higher fluorescence observed at high concentrations of cimetidine. 
Figure 9.  Graph comparing the maximum inhibition of CYP2D6 by the four drugs 
examined (F(3, 14) =12.46; p=0.006).  Cimetidine shows a statistically significant 
difference from the other three (*p<0.05). 
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The IC50 values for each compound were calculated from the fluorescence data 
using an equation provided with the inhibition kit literature by Corning: 
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The IC50 value provides a measure of drug efficiency by representing the concentration of 
drug that is needed to inhibit CYP2D6 function by half.  The quinidine IC50 was 
determined to be 12.61±3.4 nM, cimetidine was 1.1±.12 µM, MEPH was 10.1±1.0 µM, 
and BUPH was 61.7±16.0 µM (See Figure 10). 
 
 
 
 
Figure 10.  Quinidine IC50 was determined to be 12.61±3.4 nM, cimetidine was 
1.1±.12 µM, mephedrone was 10.1±1.0 µM, and buphedrone was 61.7±16.0 µM. 
A comparison of the calculated IC50 values was performed using a Kruskal-Wallis 
nonparametric 1-way ANOVA with Dunn’s Test for multiple comparisons 
(F(3,14)=12.95; p=.0012).  Buphedrone determined to be significantly different with 
from quinidine and cimetidine (*p<.05). 
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The IC50 value of BUPH was significantly different (p<0.05) from both cimetidine and 
quinidine using the Kruskal-Wallis nonparametric ANOVA with Dunn’s Test for 
multiple comparisons.  A higher concentration of BUPH is required to inhibit 50% of 
CYP2D6 activity when compared to the other three drugs.  All four drugs yielded 
positive results for inhibition of CYP2D6 and cathinone metabolism was investigated 
further using a microsomal preparation that consisted of twenty hepatic enzymes for 
evidence of metabolism. 
 
4.3 MICROSOMAL PREPARATION RESULTS 
 Human liver microsomes were incubated with MEPH or BUPH at 2µg/ml in 
duplicate (N=3) for 0, 20, 40, and 60.  The concentration of each drug was determined 
using the developed LC-MS/MS method with the same standard curve Figures 11 and 12 
illustrate the changes in concentration of both drugs over the course of an hour. 
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Figure 11.  Plot of the change in mephedrone concentration over course 
of a one hour incubation with the hepatic enzyme mix. 
Figure 12.  Plot of the change in buphedrone concentration over course 
of a one hour incubation with the hepatic enzyme mix. 
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There were no significant changes in either MEPH or BUPH contraction as a function of 
time (1-way ANOVA; F=.6447 and .0966 for MEPH and BUPH respectively). 
 
4.4 CONCLUSION 
 The results demonstrate that the developed LC-MS/MS method is linear from a 
lower limit that ranges from 1 to 10 ng/ml (depending on the analyte) to an upper limit 
25ng/ml for all analytes.  The CYP2D6 inhibition assay demonstrated that quinidine, 
cimetidine, BUPH, and MEPH all inhibited CYP2D6 activity in a concentration-dependent 
manner.  There was no apparent loss of either cathinone following incubation with the 
human liver microsomal preparation.  One possible reason for this lack of effect would be 
that neither compound is directly metabolized by CYP2D6.  Assays were performed 
essentially as described by the manufacturer.  A possible confounding factor with these 
findings is a non-optimized reaction.  It is possible that CYP2D6 protein content in the 
microsomes was too small to adequately metabolize either cathinone.  Further study would 
be needed to examine the various parameters involved with optimizing the assay.  The 
causes and implications of these findings will be discussed in the next chapter. 
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CHAPTER V 
 
 
DISCUSSION 
 
5.1 CATHINONE-ENZYME INTERACTION 
 The purpose of this research was to develop a method of detection for synthetic 
cathinones and to use the method to support an investigation of synthetic cathinone 
metabolism.  The concentration of neither BUPH nor MEPH decreased when incubated 
with the hepatic enzyme mixture; neither cathinone was metabolized by the enzymes 
present.  However, both compounds inhibited CYP2D6 metabolism of AMMC in the 
inhibition assay study with IC50 value of 10.1±1.0µM for MEPH and 61.7±16.0µM for 
BUPH.  When considered in conjunction, these two experiments suggest that the synthetic 
cathinones tested inhibited CYP2D6 activity but are not metabolized.  This could mean 
that the cathinones are affecting the catalytic site but are not being metabolized, or that 
they are affecting a site away from the catalytic site and are allosterically inhibiting enzyme 
action. 
 Synthetic cathinones are relatively novel compounds and their research can be a 
difficult task because they are scheduled controlled substances.  The research available that 
investigates cathinone metabolism specifically is even more infrequent, attesting to this 
study’s value as a contribution to the literature available on these dangerous compounds as 
they affect the body.  The data in this study contradict an earlier study which have reported
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CYP2D6 as the primary enzyme responsible for the metabolism of MEPH.29  Differing 
enzyme concentrations, reaction times, or reaction cofactors could account for the 
discrepancies between the studies.  The metabolic pathway of BUPH has yet to be 
investigated, as a result, this study provides previously unreported insight into the role of 
BUPH as a CYP2D6 inhibitor.  
  
5.2 IMPLICATIONS OF CATHINONES AS CYP2D6 INHIBITORS 
 Drug-drug interactions are a constant concern to medical treatment officials.  A 
medical history of all prescriptions and drugs taken recently is collected with any patient 
that enters the care of a physician, including recreational drug use.  When the scientific 
community does not know how synthetic cathinones affect the body, or how the body 
modifies cathinones, detecting the drugs and determining the best course of treatment 
becomes a significant challenge.  With nearly 1.3 million visits to emergency departments 
every year attributed to abused substances,3 these compounds are commonplace in 
emergency department settings.  Illicit drugs are not screened for drug-drug interactions as 
pharmaceuticals are, and therefore pose a significant risk to patients treated for injuries or 
illness while under the effects these dangerous compounds, especially when their 
metabolism is not well understood.   
When investigating drug metabolism, phase I reactions are a likely starting point 
for small molecules.  Some key CYPs include CYP3A4, CYP2C9 and CYP2D6.  CYP2D6 
is an enzyme that metabolizes a large number of xenobiotics (~25%) and adversely 
affecting its function can lead to toxic drug reactions resulting in patient injury.34  The 
metabolic mechanism of synthetic cathinones is widely uncharacterized, leaving 
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individuals who take them susceptible to drug-drug interactions that can lead to adverse 
drug effects that can be life-threatening. 
For example, tramadol and morphine, two drugs which can be used in hospital 
settings to treat a patient’s pain should they suffer injury while under the effects of synthetic 
cathinones (such as during an excited delirium), are both metabolized by CYP2D6.35-36  If 
a patient were exposed to synthetic cathinones and subsequently administered tramadol by 
a health professional (or another drug metabolized by CYP2D6) to treat any injury 
secondary to cathinone exposure, the substrate will remain in the plasma for a longer 
duration due to the inhibition of CYP2D6 by synthetic cathinones.  A heightened tramadol 
concentration in the plasma can lead to symptoms typically associated with an overdose 
such as lethargy, nausea, tachycardia, or more serious symptoms if the drug-drug 
interaction is not anticipated.37  By presenting emergency physicians and medical 
professionals with a characterization of synthetic cathinone metabolism, adverse drug 
reactions due to drug interaction may be prevented. 
Additionally, many synthetic cathinone users are polydrug users, taking more than 
one drug at a time leaving them vulnerable to illicit drug-drug interactions long before they 
are treated for exposure.31-32  Methamphetamine, for example, acts as a weakly binding 
substrate for CYP2D6 but approximately 50% of all methamphetamine metabolites 
excreted utilize CYP2D6.38-39  CYP2D6 is responsible for half of the elimination of any 
methamphetamine consumed.  When taken alongside synthetic cathinones, 
methamphetamine will stay in the plasma longer, increasing the likelihood that the user 
will experience adverse drug reactions and overdose.  However, it is a possibility that other 
metabolic pathways would be capable of making up for the inhibition of CYP2D6 by 
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metabolizing more of the methamphetamine.  The interaction between synthetic cathinones 
and methamphetamine (and other drugs such as alcohol, over the counter drugs, or drugs 
that may be consumed simultaneously with synthetic cathinones) needs to be investigated 
further. 
 While there was no metabolic activity observed in the hepatic enzyme mixture, 
there is likely activity with other enzymes.  Synthetic cathinone metabolites have been 
observed in urine28,30 suggesting that between ingestion and excretion, an enzymatic 
process (or another non-enzymatic process such as spontaneous degradation in plasma) is 
modifying the compound; however, currently that process is not known.  The enzymes 
tested are those involved in Phase I metabolism, which attempts to introduce polar groups 
onto substrates to increase the water solubility of the compound and increase its rate of 
elimination.40  It is a possibility that synthetic cathinones are acted on by enzymes involved 
primarily in Phase II metabolism, which typically involves conjugating xenobiotics and 
making them less active before excretion.41  Although this project did not investigate the 
metabolism of the synthetic cathinone MDPV, Strano-Rossi et al. demonstrated that the 
main metabolites of MDPV were sulfated and glucoronated.42  MEPH or BUPH could 
follow a similar metabolic pathway.  The more information available to scientists and 
medical professionals about the metabolism of synthetic cathinones, the better prepared 
they are to handle individuals who are under the influence of these dangerous drugs. 
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5.3 Future Work 
 While there were several questions answered by this project concerning cathinone 
enzymatic activity, there are many other questions about synthetic cathinone metabolism 
that have yet to be addressed.  It was discovered that synthetic cathinones act as a CYP2D6 
inhibitor, yet the mechanism of inhibition is still unknown.  A competitive inhibition would 
arise when the cathinone occupies the active site of the enzyme, preventing the substrate 
from accessing the site.  Noncompetitive inhibition mechanism can involve an inhibitor 
that binds at a site separate from the substrate active site but still hampering enzyme 
function by allosterically altering the active site and inhibiting substrate binding.  
Noncompetitive inhibition could alternatively involve a cathinone covalently binding to 
the enzyme and inhibiting substrate binding.  Determining the mechanism of inhibition 
could help physicians handle individuals who are exposed to synthetic cathinones more 
effectively.  Knowing that the CYP2D6 enzyme is blockaded (and how it is blockaded) 
may influence treatment decisions.  While tramadol and morphine are opioids which utilize 
CYP2D6, ketamine which provides pain relief and sedation and is metabolized primarily 
by CYP3A4 can be a useful alternative to avoid adverse drug effects.43   
 Further research to identify the enzyme responsible for synthetic cathinone 
metabolism and elimination also has many applications.  An understanding of cathinone 
metabolism can lead to an explanation of the neurological and cardiac symptoms observed 
in individuals following such synthetic cathinone exposure, such as excited delirium which 
poses a danger to both exposed individuals and those around them.23,27  Forensically, the 
detection of a drug metabolite is often preferable because it allows investigators to detect 
illicit drug exposure long after the parent drug has been metabolized and is no longer found 
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in biological samples.  By identifying the enzymes involved in synthetic cathinone 
metabolism, it may give investigators the information they need to locate detectable 
metabolites and expand their window of synthetic cathinone detection.  Additionally, 
identification of the enzymes responsible for cathinone metabolism can help predict 
cathinone’s affect when taken simultaneously with other drugs and aid death 
investigations. 
 Another avenue of exploration includes the effects of other cathinone analogues on 
CYP2D6 (and other enzymes).  Because they have different structures it is likely that they 
will react with the body differently from one analogue to the next.  This could be in the 
form of varying affinities for CYP2D6, or action on another enzyme altogether.  Different 
metabolic pathways would likely lead to varying physiological effects such as different 
symptoms observed, varying symptom intensity, and varying symptom duration.  While 
the developed method has proven capable of distinguishing one cathinone analogue from 
the next during sample analysis, there is not information available on how the different 
analogues are going to affect someone after ingestion. 
 These are just a few of many avenues of research that could be explored on the 
topic of synthetic cathinones and their metabolism.  Because such little information about 
their enzymatic activity currently exists, the field is wide open to future projects.  With the 
addition of new cathinone analogues every year, this field is only going to expand. 
 
5.4 Discussion Summary 
 This research illustrates that synthetic cathinones, specifically BUPH and MEPH 
act as CYP2D6 inhibitors by observing their enzymatic action.  As an inhibitor of an 
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enzyme that metabolizes many xenobiotics, synthetic cathinones present a significant risk 
for drug-drug interactions.  By studying the metabolic effects healthcare professionals can 
account for the inhibition of CYP2D6 and prevent adverse drug reactions.  Both forensic 
experts and medical professionals would benefit from research further studying synthetic 
cathinone metabolism and identify the enzymes involved in its metabolism and 
elimination. 
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CHAPTER VI 
 
 
CONCLUSION 
 Recent surveys demonstrate that the illicit drug problem affects millions of 
individuals nationwide.  Synthetic cathinones are a dangerous novel drug which present a 
significant threat to individuals throughout the United States.  Detection methods capable 
of quantifying drug concentration must be updated regularly to adapt to the most recent 
analogues produced by illicit drug manufacturers as they attempt to avoid detection and 
legislative repercussions.  Synthetic compounds are also metabolically uncharacterized and 
present a problem as medical professionals attempt to treat for an illicit drug exposure the 
scientific community knows very little about.  This may manifest in unanticipated drug-
drug interactions which can potentially be life threatening.  This study presents a method 
of detecting several of the most popular synthetic cathinones and an investigation into their 
metabolism that addresses the need of both the forensic and medical communities as they 
attempt to handle individuals who have been exposed synthetic cathinones. 
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APPENDICES 
 
A1.  Observed fluorescence intensity at their corresponding concentrations of quinidine 
(n=4).  Each repetition was a result of two wells that were averaged (four wells were 
averaged for the controls).  From these values the percent total fluorescence was 
calculated. 
Quinidine: [µM]               
Concentration: 1 0.33 0.11 0.037 0.012 0.004 0.0013 0.003 
Fluorescence 
Intensity: 
7624 7780 7970 8424 8641 9009 9134 9225 
7714 7893 8038 8178 8531 8906 9168 9306 
Pooled Intensity: 7669 7836.5 8004 8301 8586 8957.5 9151 9265.5 
% Total 
Fluorescence: 5.62% 15.43% 25.23% 42.62% 59.31% 81.06% 92.39% 99.09% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9157 9327 7521 7393         
  9269 9372 7581 7800         
Pooled Intensity:   9281.25   7573.75         
                  
Concentration: 1 0.33 0.11 0.037 0.012 0.004 0.0013 0.003 
Fluorescence 
Intensity: 
6668 6336 6447 6634 6998 7403 7689 7806 
6781 6384 6633 6585 6974 7572 7600 7642 
Pooled Intensity: 6724.5 6360 6540 6609.5 6986 7487.5 7644.5 7724 
% Total 
Fluorescence: 30.60% 7.91% 19.12% 23.44% 46.89% 78.11% 87.89% 92.84% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 7900 7839 6241 6204         
  7768 7850 6280 6208         
Pooled Intensity:   7839.25   6233.25         
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Concentration: 1 0.33 0.11 0.037 0.012 0.004 0.0013 0.003 
Fluorescence 
Intensity: 
6649 6337 6461 6558 6963 7289 7586 7638 
6775 6322 6684 6626 6922 7313 7559 7682 
Pooled 
Intensity: 6712 6329.5 6572.5 6592 6942.5 7301 7572.5 7660 
% Total 
Fluorescence: 28.69% 3.92% 19.66% 20.92% 43.62% 66.84% 84.42% 90.09% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 7781 7774 6234 6361         
  7774 7926 6208 6275         
Pooled 
Intensity:   7813.75   6269.5         
                  
Concentration: 1 0.33 0.11 0.037 0.012 0.004 0.0013 0.003 
Fluorescence 
Intensity: 
7625 7329 7506 7998 8423 9028 9167 9082 
7811 7525 7681 8115 8540 9026 9099 9190 
Pooled 
Intensity: 7718 7427 7593.5 8056.5 8481.5 9027 9133 9136 
% Total 
Fluorescence: 29.74% 15.67% 23.72% 46.11% 66.66% 93.04% 98.16% 98.31% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9173 9104 7154 7038         
  9218 9191 7174 7047         
Pooled 
Intensity:   9171.5   7103.25         
 
 
 
 
 
 
 
 
 
 
(A1 Continued) 
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A2.  Observed fluorescence intensity at their corresponding concentrations of 
mephedrone (n=5).   Each repetition was a result of two wells that were averaged (four 
wells were averaged for the controls).  From these values the percent total fluorescence 
was calculated. 
Mephedrone: [µM]               
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
7392 8080 8629 9146 9291 9391 9417 9318 
7277 8339 8540 9163 9427 9849 9271 9600 
Pooled Intensity: 7334.5 8209.5 8584.5 9154.5 9359 9620 9344 9459 
% Total 
Fluorescence: -30.21% 23.47% 46.47% 81.44% 93.99% 110.00% 93.07% 100.12% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9466 9327 7845 7778         
  9532 9504 7953 7732         
Pooled Intensity:   9457.25   7827         
                  
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
6735 6527 7182 7452 7701 7922 7761 7801 
6748 6604 7044 7305 7878 7768 7803 7715 
Pooled Intensity: 6741.5 6565.5 7113 7378.5 7789.5 7845 7782 7758 
% Total 
Fluorescence: 33.61% 23.57% 54.79% 69.93% 93.36% 96.52% 92.93% 91.56% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 7854 7967 6203 6099         
  7880 7925 6185 6123         
Pooled Intensity:   7906.5   6152.5         
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Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
6717 6812 7064 7476 7964 7826 7752 7705 
6631 6701 7237 7617 7807 8066 7923 8317 
Pooled Intensity: 6674 6756.5 7150.5 7546.5 7885.5 7946 7837.5 8011 
% Total 
Fluorescence: 33.79% 38.14% 58.91% 79.78% 97.65% 100.84% 95.12% 104.27% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 7985 7788 6145 5898         
  8004 7943 6160 5929         
Pooled Intensity:   7930   6033         
                  
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
7822 7668 8065 8554 8619 8710 8751 8754 
7818 7713 8185 8553 8665 8693 8708 8741 
Pooled Intensity: 7820 7690.5 8125 8553.5 8642 8701.5 8729.5 8747.5 
% Total 
Fluorescence: 54.17% 47.20% 70.60% 93.67% 98.44% 101.64% 103.15% 104.12% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 8733 8615 6857 6762         
  8660 8678 6963 6674         
Pooled Intensity:   8671.5   6814         
                  
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 7876 7776 8251 8569 8676 8826 8856 8657 
  7701 7708 8353 8491 8877 8860 8916 8891 
Pooled Intensity: 7788.5 7742 8302 8530 8776.5 8843 8886 8774 
% Total 
Fluorescence: 45.13% 42.68% 72.16% 84.16% 97.13% 100.63% 102.89% 97.00% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 8845 8892 7019 6969         
  8875 8715 6911 6828         
Pooled Intensity:   8831.75   6931.75         
(A2 Continued) 
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A3.  Observed fluorescence intensity at their corresponding concentrations of 
buphedrone (n=5).  Each repetition was a result of two wells that were averaged (four 
wells were averaged for the controls).  From these values the percent total 
fluorescence was calculated. 
Buphedrone: [µM]               
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
7340 7693 9129 8218 8064 8126 8004 8201 
7343 7501 8283 8304 8236 8188 7898 8295 
Pooled Intensity: 7341.5 7597 8706 8261 8150 8157 7951 8248 
% Total 
Fluorescence: 56.91% 73.04% 143.06% 114.96% 107.95% 108.40% 95.39% 114.14% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 7901 8199 6454 6483         
  7884 8113 6365 6459         
Pooled Intensity:   8024.25   6440.25         
                  
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
7374 7651 8204 8033 8294 8166 8204 8296 
7165 7290 8126 8159 8265 8140 8278 8311 
Pooled Intensity: 7269.5 7470.5 8165 8096 8279.5 8153 8241 8303.5 
% Total 
Fluorescence: 46.12% 58.40% 100.86% 96.64% 107.85% 100.12% 105.50% 109.32% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 8069 8143 6387 6313         
  8192 8201 6984 6376         
Pooled Intensity:   8151.25   6515         
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Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
7340 7500 8118 8153 8465 8139 8282 8309 
7148 6697 7558 8066 8366 8190 8148 8484 
Pooled 
Intensity: 7244 7098.5 7838 8109.5 8415.5 8164.5 8215 8396.5 
% Total 
Fluorescence: 49.94% 41.34% 85.05% 101.09% 119.18% 104.34% 107.33% 118.06% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 8078 8134 6552 6319         
  8080 8073 6434 6291         
Pooled 
Intensity:   8091.25   6399         
                  
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
8073 8473 9126 9382 9494 9384 9393 9480 
8025 8532 9218 9342 9408 9600 9499 9352 
Pooled 
Intensity: 8049 8502.5 9172 9362 9451 9492 9446 9416 
% Total 
Fluorescence: 39.97% 61.07% 92.23% 101.07% 105.21% 107.12% 104.98% 103.58% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9272 9397 7183 7188         
  9199 9489 7307 7083         
Pooled 
Intensity:   9339.25   7190.25         
                  
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 8019 8675 9228 9368 9354 9590 9619 9438 
  7877 8713 9393 9409 9427 9537 9546 9419 
Pooled 
Intensity: 7948 8694 9310.5 9388.5 9390.5 9563.5 9582.5 9428.5 
% Total 
Fluorescence: 32.68% 66.07% 93.67% 97.16% 97.25% 104.99% 105.84% 98.95% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9399 9469 7279 7237         
  9385 9556 7233 7126         
Pooled 
Intensity:   9452.25   7218.75         
(A3 Continued) 
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A4.  Observed fluorescence intensity at their corresponding concentrations of 
cimetidine (n=4).  Each repetition was a result of two wells that were averaged (four 
wells were averaged for the controls).  From these values the percent total 
fluorescence was calculated. 
Cimetidine: [µM]               
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
8938 9140 9267 9325 9334 10042 9444 9930 
8794 9186 9242 9275 9378 10055 9198 9961 
Pooled Intensity: 8866 9163 9254.5 9300 9356 10048.5 9321 9945.5 
% Total 
Fluorescence: 63.95% 77.62% 81.84% 83.93% 86.51% 118.39% 84.90% 113.65% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9469 9560 7447 7447         
  9749 9821 7508 7508         
Pooled Intensity:   9649.75   7477.5         
                  
Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
8846 9091 9232 9392 9194 9866 9240 9879 
9079 9252 9213 9277 9280 10079 9269 9827 
Pooled Intensity: 8962.5 9171.5 9222.5 9334.5 9237 9972.5 9254.5 9853 
% Total 
Fluorescence: 71.24% 81.61% 84.14% 89.70% 84.86% 121.36% 85.73% 115.43% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9184 9301 7538 7538         
  9169 9278 7601 7601         
Pooled Intensity:   9233   7569.5         
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Concentration: 100 33 11 3.7 1.2 0.4 0.14 0.05 
Fluorescence 
Intensity: 
8918 9092 9221 9293 9117 9855 9217 9927 
9060 9279 9215 9282 9334 10156 9362 10035 
Pooled Intensity: 8989 9185.5 9218 9287.5 9225.5 10005.5 9289.5 9981 
% Total 
Fluorescence: 69.49% 77.90% 79.29% 82.26% 79.61% 112.99% 82.35% 111.94% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9514 9247 7518 7518         
  9230 9275 7536 7536         
Pooled Intensity:   9316.5   7527         
                  
Concentration: 1 0.33 0.11 0.037 0.012 0.004 0.0013 0.003 
Fluorescence 
Intensity: 
8073 8473 9126 9382 9494 9384 9393 9480 
8025 8532 9218 9342 9408 9600 9499 9352 
Pooled Intensity: 8049 8502.5 9172 9362 9451 9492 9446 9416 
% Total 
Fluorescence: 39.97% 61.07% 92.23% 101.07% 105.21% 107.12% 104.98% 103.58% 
                  
Concentration: 0   Blank           
Fluorescence 
Intensity: 9293 9330 7213 7434         
  9247 9370 7415 7364         
Pooled Intensity:   9310   7356.5         
(A4 Continued) 
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A5.  Observed concentrations from the microsomal 
preparation over a one hour incubation.  Each 
repetition (n=3) was from two pooled wells. 
Buphedrone     
Time 
(min) 
Observed 
Concentration 
(ng/ml) 
Pooled 
Concentration 
(ng/ml) 
Mean 
Concentration 
(ng/ml) 
0 191.70 185.10 204.05 
  178.50     
  196.80 201.40   
  206.00     
  205.90 225.65   
  245.40     
20 207.00 200.40 208.78 
  193.80     
  197.90 199.40   
  200.90     
  214.90 226.55   
  238.20     
40 200.40 206.20 207.63 
  212.00     
  203.40 207.60   
  211.80     
  209.10 209.10   
  ---     
60 201.70 212.40 204.15 
  223.10     
  196.30 204.25   
  212.20     
  195.80 195.80   
  ---     
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A6.  Observed concentrations from the microsomal 
preparation over a one hour incubation.  Each 
repetition (n=3) was from two pooled wells. 
Mephedrone     
Time 
(min) 
Observed 
Concentration 
(ng/ml) 
Pooled 
Concentration 
(ng/ml) 
Mean 
Concentration 
(ng/ml) 
0 202.10 194.30 188.73 
  186.50     
  188.10 185.55   
  183.00     
  186.90 186.35   
  185.80     
20 166.00 181.40 186.42 
  196.80     
  182.50 185.30   
  188.10     
  180.40 192.55   
  204.70     
40 202.10 224.15 195.15 
  246.20     
  187.60 186.10   
  184.60     
  187.10 175.20   
  163.30     
60 193.30 211.55 198.92 
  229.80     
  180.90 199.15   
  217.40     
  184.40 186.05   
  187.70     
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